Tiny Health, Audited: The Baby Gut Test That Actually Ran a Trial

The consumer microbiome business has a validation problem it mostly prefers not to discuss. Federal measurement scientists reported in June that home gut tests give varying results; when we sent one stool sample to seven labs, we got seven different answers; and no company in the category had ever put its own product through a randomized controlled trial and published what happened. Then, last year, one did — and it was not one of the venture-funded adult-wellness giants. It was the baby one. Whatever else is true of Tiny Health, it has done the single thing this publication keeps saying the industry never does, which earns it the closest read we can give.

The founderWho is Cheryl Sew Hoy?

Tiny Health began the way the best health companies tend to: with a problem in the founder’s own house. Cheryl Sew Hoy, a serial tech entrepreneur, founded the company in 2020 after her first child struggled with eczema, sleep troubles and food sensitivities — and after she went looking for answers about the infant gut and found that nobody would test it. Two years of R&D later, in 2022, Tiny Health launched the first at-home gut microbiome test built for babies. The bet has compounded: more than $10 million in revenue in 2025 and on track to nearly triple that by the end of 2026, per Inc., plus NutraIngredients-USA’s Start-up of the Year award in 2025.

The productWhat does Tiny Health actually test?

The thesis is the first 1,000 days: the gut microbiome assembles in infancy, and disruptions to that assembly — C-section birth is the best-studied — are associated in the research with higher rates of allergic and inflammatory conditions later. Tiny Health’s tests now span baby, child, adult, pregnancy and vaginal health, on a membership priced at $399 a year. A swab sample goes to a CLIA lab; the company says it screens more than 120,000 microbes — bacteria, fungi, viruses, parasites, archaea — runs gene-level functional analysis, and checks findings against an internal reference set of real metagenomic samples, with results in two to three weeks and a personalized action plan attached.

The trialWhat did the study actually measure?

Here is the piece of paper the rest of the shelf does not have. In a randomized controlled trial published in Pediatric Allergy and Immunology in 2025, researchers enrolled 54 full-term babies born by C-section — the delivery mode with the best-documented microbiome disruption — and randomized them: 25 to six months of Tiny Health’s program (microbiome testing, personalized nutrition and probiotic guidance, and coaching from the company’s specialists), 29 to usual care. By the study’s end, 6 percent of the intervention babies had developed eczema against 29 percent of controls — an 83 percent reduction in the odds. The intervention group’s microbiomes also shifted measurably. It is a real trial, in a real peer-reviewed journal, with a hard clinical endpoint. In this category, that is close to unheard of.

The honest asterisksHow much can 54 babies prove?

Now the same close read we give everyone. Fifty-four infants is small — behind those tidy percentages sit single-digit case counts, which is why the confidence interval on that 83 percent is wide. The trial was company-run, not independent. And the intervention was a bundle — testing plus personalized guidance plus coaching — so the design cannot say which ingredient did the work, or whether the test itself (rather than, say, six months of expert attention) moved the needle. None of this is a scandal; these are the ordinary limits of a first proof-of-concept trial, the same ones we noted on Pendulum’s diabetes study. The difference between a first trial and a marketing claim is whether a bigger, independent replication follows. That is the next thing to watch for.

The bigger pictureWhere this sits on the shelf

Read this piece next to our audit of Jona and the shape of the category comes into focus: sequencing is largely a solved problem, interpretation is not, and the companies differ most in how honestly they handle that gap. Tiny Health’s answer — narrow the question to infancy, where the science of microbiome assembly is strongest, and then actually test your program against a clinical outcome — is the most scientifically serious posture we have found in consumer microbiome testing. It does not make the reports gospel; interpretation of any individual baby’s swab still rests on a young, shifting literature, and $399 a year is real money. It does mean the company has accepted the standard the rest of the industry avoids: run the trial, publish the result, live with the asterisks.

The bottom lineWhat should a parent make of it?

If your child has eczema, feeding trouble or suspected allergies, the first stop is a pediatrician, not a swab — and nothing in Tiny Health’s trial changes that. What the trial does support, modestly and specifically, is that for C-section babies, a structured six-month program of microbiome-guided nutrition and probiotic support was associated with meaningfully less eczema in one small randomized study. Parents weighing the membership should read the study’s limits as plainly as its headline — and companies hoping to sell tests to the rest of us should study what earning coverage like this actually took: a trial. This audit is part of Gut Check, our running evidence review of the gut-health industry. It is educational and is not medical advice.